and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the presentation of new data from its ongoing Phase 1/2 study, KB-0742-1001, a first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma, in a poster session at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting being held from May 31 – June 4, 2024 in Chicago, Illinois and online.

和马萨诸塞州剑桥市，2024年5月23日（环球通讯社）--Kronos Bio，Inc.（纳斯达克代码：KRON），一家致力于开发小分子治疗药物的公司，致力于解决由转录失调驱动的癌症和其他疾病，今天宣布在2024年5月31日至6月4日于伊利诺伊州芝加哥举行的2024年美国临床肿瘤学会（ASCO）年会的海报会议上，展示其正在进行的1/2期研究KB-0742-1001的新数据，这是首次对复发或难治性实体瘤或非霍奇金淋巴瘤患者进行KB-0742的人体开放标签剂量递增和队列扩展研究。

“We are pleased that KB-0742 continues to demonstrate a manageable safety and tolerability profile as it progresses through dose escalation,” said Norbert Bischofberger, Ph.D., president and chief executive officer, Kronos Bio, Inc. “These data indicate a deepening reduction of CDK9-sensitive transcripts at the 80mg dose as compared to the 60mg dose.

Kronos Bio，Inc.总裁兼首席执行官Norbert Bischofberger博士说：“我们很高兴KB-0742在剂量递增的过程中继续表现出可控的安全性和耐受性。这些数据表明，与60mg剂量相比，80mg剂量的CDK9敏感转录本的减少程度加深。

In addition, MYC reductions were observed in paired biopsy tumor tissues. This data provides us with confidence that the 80mg four-days-on, three-days-off dose and schedule will show increased patient benefit. We are currently enrolling the dose escalation arm at the 80mg four-days-on, three-days-off sch.

此外，在成对的活检肿瘤组织中观察到MYC减少。这些数据使我们有信心，80mg四天服用，三天不服用剂量和时间表将显示患者获益增加。我们目前正在登记剂量递增组，剂量递增组为80mg，为期四天，休息三天。